-
Study Led by Dr. Jianhong Zhong Explores Optimal Duration of Adjuvant Immune Checkpoint Inhibitors After Hepatectomy in High-Risk HCC
Background and Objective Hepatocellular carcinoma (HCC) is among the most common malignancies globally, with a high recurrence rate after resection, especially in patients with risk factors like large tumor size,…
-
2025 Peking University Urology Academic Forum | Prof. Changwen Zhang (The Second Hospital of Tianjin Medical University)
Prof. Changwen Zhang presented a comprehensive update on the Chinese clinical exploration of ADC-based therapies in urothelial carcinoma. His presentation highlighted the promising role of Vedicitumab (RC48), a HER2-targeted ADC,…
-
2025 Peking University Urology Academic Forum | Prof. Qi Tang (Peking University First Hospital)
In this comprehensive presentation, Prof. Qi Tang shared the construction, organization, and future roadmap of the UTUC subspecialty team at Peking University First Hospital. The presentation highlighted the integration of…
-
2025 Peking University Urology Academic Forum | Prof. Shan Liu
In his insightful presentation, Prof. Shan Liu shared an in-depth look into China’s rapidly evolving surgical robot ecosystem, highlighting the comprehensive technical support and advanced maintenance services provided for robotic…
-
Clin Cancer Res | Prospective Multicenter Study Led by Dr. Xiaofan Zhu and Dr. Min Ruan Evaluates Venetoclax Plus Reduced-Intensity Chemotherapy in Newly Diagnosed Pediatric AML
Acute myeloid leukemia (AML) is a highly heterogeneous clonal malignancy, accounting for approximately 15–20% of pediatric leukemia cases. The current standard first-line induction regimen, known as “3+7,” achieves complete remission (CR) rates of approximately 70%. However, about 25% of pediatric patients eventually progress to relapsed/refractory AML (R/R AML), associated with poor prognosis.
Connecting Medical Expertise through Media
